Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
COGT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.72 - $13.50
Previous CloseN/A
Volume181.15K
Average Volume (3M)1.61M
Market Cap
$1.75B
Enterprise Value$752.59M
Total Cash (Recent Filing)$237.85M
Total Debt (Recent Filing)$60.66M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Nov 17, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding139,700,790
10 Day Avg. Volume2,267,350
30 Day Avg. Volume1,611,110
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue175.35
Enterprise Value/Gross Profit-6.97K
Enterprise Value/Ebitda-2.62
Forecast
1Y Price Target
$20.92Price Target Upside57.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyBezuclastinib's design as a more selective drug allows for greater efficacy with fewer side effects than prior KIT inhibitors.
Financial PositionCogent ended 2Q25 with roughly $453M in pro forma cash and cash equivalents, which should provide an operational runway into 2027; this window spans the expected timing of the clinical readouts from the ongoing PEAK and APEX registration-directed trials.
Market OpportunityBezuclastinib has the potential to address a collective $3 billion U.S. total addressable market across all three indications.
Bears Say
Market ConcernsThe company changed the timing guidance for PEAK readout to 2H25, generating questions from some investors who were concerned that the change may signal that the bezu arm may be underperforming.
Regulatory And Development RisksRisks include, but are not limited to: negative clinical data, particularly for bezuclastinib; slower-than-expected development timelines; setbacks in later-stage trials; failure to obtain regulatory approvals; setbacks with earlier-stage candidates, notably the FGFR2 and ErbB2 programs; lower-than-projected commercial success; and long-term dilution risk.
Cogent Biosciences News
COGT FAQ
What was Cogent Biosciences’s price range in the past 12 months?
Cogent Biosciences lowest stock price was $3.72 and its highest was $13.50 in the past 12 months.
What is Cogent Biosciences’s market cap?
Cogent Biosciences’s market cap is $1.75B.
When is Cogent Biosciences’s upcoming earnings report date?
Cogent Biosciences’s upcoming earnings report date is Nov 17, 2025 which is in 51 days.
How were Cogent Biosciences’s earnings last quarter?
Cogent Biosciences released its earnings results on Aug 05, 2025. The company reported -$0.595 earnings per share for the quarter, missing the consensus estimate of -$0.587 by -$0.008.
Is Cogent Biosciences overvalued?
According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued.
Does Cogent Biosciences pay dividends?
Cogent Biosciences does not currently pay dividends.
What is Cogent Biosciences’s EPS estimate?
Cogent Biosciences’s EPS estimate is -0.53.
How many shares outstanding does Cogent Biosciences have?
Cogent Biosciences has 139,700,790 shares outstanding.
What happened to Cogent Biosciences’s price movement after its last earnings report?
Cogent Biosciences reported an EPS of -$0.595 in its last earnings report, missing expectations of -$0.587. Following the earnings report the stock price went down -5.726%.
Which hedge fund is a major shareholder of Cogent Biosciences?
Currently, no hedge funds are holding shares in COGT
Cogent Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.92 (57.89% Upside)
$20.92 (57.89% Upside)
Blogger Sentiment
Bullish
COGT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 685.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.11%
12-Months-Change
Fundamentals
Return on Equity
-107.55%
Trailing 12-Months
Asset Growth
-36.08%
Trailing 12-Months
Company Description
Cogent Biosciences
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
COGT Stock 12 Month Forecast
Average Price Target
$20.92
▲(57.89% Upside)
Technical Analysis
IDEAYA Biosciences
―
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
6.48% Insiders
17.53% Mutual Funds
54.28% Other Institutional Investors
11.46% Public Companies and
Individual Investors